Medimabs

Comme avec l’origami, on ne termine pas toujours avec un cygne. Conformères mal repliés de SOD1 et la . https://bit.ly/3r3vGuB As with origami, you don't always end up with a swan. SOD1 misfolded conformers and . https://bit.ly/434l4ZG

As with origami, you don't always end up with a swan. SOD1 misfolded conformers and ALS. - MediMabs Protein folding is like doing origami where the amino acid sequence dictates how the protein folds to form its final 3D structure. This three-dimensional structure is essential to the proper functioning of the protein, and the same protein can be found in several conformations known as conformers. D...

Cibler le bon suspect : Stratégies de vaccination par l’ADN dans la maladie d’Alzheimer https://bit.ly/43syH6d Targeting the right suspect: DNA Vaccination strategies in https://bit.ly/3qjH7y0

Targeting the right suspect: DNA Vaccination strategies in Alzheimer’s Disease - MediMabs Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders and the most common cause of dementia. It is characterized by the aggregation of amyloid β protein (Aβ) into extracellular plaques in the brain and the accumulation of neurofibrillary tangles containing tau protein wi...

Identifier les réservoirs inductibles et compétents pour la réplication: trouver une aiguille dans une botte de foin. https://bit.ly/40Tyve1 Identify inducible and replication-competent reservoirs: finding a needle in a haystack. https://bit.ly/44flU7M

Radioactive payload attached to cancer-specific antibodies. https://bit.ly/3t0DCuV Charge utile radioactive couplée à des anticorps comme thérapie du cancer. https://bit.ly/3PLDQQk

Stop playing Whac-A-Mole with HIV: A promising new therapeutic strategy. https://bit.ly/3vxMiqT

Stop playing Whac-A-Mole with HIV: A promising new therapeutic strategy. | MediMabs Due to the HIV’s capacity to hide into different cell reservoirs, an effective therapy would be to reduce the viral load and limit the virus’s resurgence in the event of treatment interruption. Over the past couple of decades, various strategies have been developed to reduce the viral load in HI...

Better than swatting mosquitoes: A potential target to stop Zika from replicating. Read more http://bit.ly/3knVKt2

Antibodies dedicated to your cause! 2 new articles citing our McSA1 clone and a new website to serve you better! Read more: http://bit.ly/2Z4lEbm IG Agence créative

Wouldn’t it be sweet to be able to make antibodies against sugars. https://bit.ly/2MsfawM

Another string to our bow against http://bit.ly/2TRsZb7

Thwarting disease through lithium microdosing http://bit.ly/3bMmcrF

Combating Coronavirus: The road to making a vaccine. http://bit.ly/2RGEaUs

Vectored Immunoprophylaxis: delivering mAb’s blueprints directly into the host cells. http://bit.ly/3754ooO

IntelliStem partners with MédiMabs to create a biotech powerhouse platform ™ http://bit.ly/35h7qVQ

The exhumation of a possible treatment against the “brain-eating” disease . http://bit.ly/2PGAZeV

Epithelial-Mesenchymal Transition in : the example of E-cadherin http://bit.ly/2kuge95

Individually united, the advantage of Parallex Bioassays multiple singleplexing solution. The AKT pathway example. http://bit.ly/30JdWT6

The strong connection between gut and immunotherapy. http://bit.ly/2ZhVdwo

PSMA as a theranostic target http://bit.ly/2xCxPOT

Cell adhesion molecule CD146 and skin . Sunny days are here to stay, don’t forget to protect yourself from UV rays. http://bit.ly/2W2KRny

Happy Valentine’s day! When one and one make two. Dimerization, an important process in signal transduction. http://bit.ly/2SwUJnI

The promise of FGFR inhibitors in the clinic, but which FGFR isoform drives ? http://bit.ly/2HKvI3p

Best wishes from your specialist. We wish you a very Happy Holiday season and a peaceful and prosperous New Year.

Research on neurodegenerative disease has always been in important at MédiMabs. http://bit.ly/2pky0tV

MédiMabs | Neurosciences Research on neurodegenerative disease has always been in important at MédiMabs. Partly because two of our founders have dedicated their career to this field of research and partly because we are all touched by these at different levels in our personal life. We always feel proud and implicated when ...

It’s that time of the year again! Ask our specialists what they can do to help you get ready to generate tons of statistically significant results. http://bit.ly/2O9U99n

Learn more about FGFR isoforms profile relevance in cancer research. http://bit.ly/2oUArmU

We are pleased to announce you that we have set an official agreement with the CCAB for the commercialization of their research reagents under the brand MédiMabs - CCAB series. http://bit.ly/2O50xP9

We will be at the Biotech-connect show of MaRS center next week on Thursday September 13th. Come and visit us at our booth. http://bit.ly/2CpSxqj

MédiMabs | MaRS show on September 13th 2018 MaRS research center is public and private initiative with the goal of filling the gap between academic research and private commercialization. It will be our pleasure to meet you at our booth during the Biotech-connect event on September 13th. We will be ready to answer your questions and help you....

We are pleased to announce you that we’ve recently officially launched our new website. http://bit.ly/2NiU320

Medimabs updated their address.

Medimabs updated their business hours.